Raj Makkar
Latest contributions
Hotline TAVI 2: outcomes with new and established devices
21 May 2025 – From EuroPCR 2025
Review outcomes of new and established TAVI devices through pooled analyses and multicenter studies. Topics include comparisons of balloon-expandable valves, intra- versus supra-annular self-expanding valves, and insights from the ACURATE IDE and ACURATE prime studies.
Updates in transcatheter MVR
21 May 2025 – From EuroPCR 2025
This session provides a detailed overview of recent advances in transcatheter mitral valve replacement (TMVR). Examine outcomes from next-generation transcatheter heart valves, long-term clinical data from mitral valve-in-valve and valve-in-ring procedures, and explore innovative approaches including transseptal MVR with insights from global studies.
Transcatheter tricuspid valve replacement in the real world: current data and outcomes
21 May 2025 – From EuroPCR 2025
Explore current real-world data and outcomes of transcatheter tricuspid valve replacement (TTVR). This session reviews UK single-centre experiences, registry data, long-term right ventricular remodeling effects, safety in pacemaker patients, and AI-based CT screening for patient selection.
Mitral and tricuspid hotline: long-term outcomes
20 May 2025 – From EuroPCR 2025
Review long-term outcomes of transcatheter edge-to-edge repair (TEER) for mitral and tricuspid valve disease in this session. Highlights include pivotal trial results, mortality risk prediction tools, management of procedural failures, and real-world data, providing comprehensive insights into patient prognosis and therapeutic impact.
Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis
21 May 2025 – From EuroPCR 2025
Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.
Patients with under-expanded valves faced higher risks...
Clinical and echocardiographic outcomes among the first 500 patients treated with a dedicated transcatheter aortic valve for pure aortic regurgitation in the Align-AR clinical trial
31 Mar 2025
Jonathan Curio interviews Raj Makkar about the results of the Align-AR trial which he presented during the ACC.25 in Chicago.
Author
Author
TRISCEND II: Top Late Breaking Trial at PCR London Valves 2024
26 Nov 2024 – From PCR London Valves 2024
Chiara De Biase and Raj Makkar share key insights from the TRISCEND II study. This innovative research addresses a crucial question: can transcatheter tricuspid valve replacement improve symptoms, quality of life, and clinical outcomes in patients? Listen as Makkar details the enrolled population and the study's...
Multivalve disease: defining pathways for optimal assessment and treatment in the absence of good clinical evidence
26 Nov 2024 – From PCR London Valves 2024
Curious about managing multivalve disease in the absence of robust clinical evidence? This video is a must-watch!
You'll explore the latest strategies for assessing and treating this condition (including advanced multimodality investigations like echocardiography, magnetic resonance and cardiac catheterisation), and learn how to evaluate cardiopulmonary interactions and...
TAVI for aortic regurgitation
25 Nov 2024 – From PCR London Valves 2024
Curious about advancing your knowledge in TAVI for aortic regurgitation? Don’t miss this video!
You'll dive into the diagnostic and treatment strategies to optimize outcomes in patients with aortic regurgitation, explore groundbreaking technologies like the Jenavalve Trilogy THV system and gain insights from the latest clinical evidence and...
TAVI for pure aortic regurgitation - LIVE case
25 Nov 2024 – From PCR London Valves 2024
Watch a LIVE case followed by a recorded case on aortic regurgitation:
- An 86-year-old male with a history of stroke and prostate cancer presenting acute heart failure due to severe pure aortic regurgitation and LV dysfunction (EF 39%). A 27 mm JenaValve Trilogy prosthesis was implanted without...
Insights from the top late-breaking trials at PCR London Valves 2024
24 Nov 2024 – From PCR London Valves 2024
Looking to stay ahead in transcatheter valve therapies? Don't miss out this video showcasing the most impactful late-breaking trials from PCR London Valves 2024.
Discover pivotal findings, including one-year results comparing two balloon-expandable TAVI valves, outcomes of the TRISCEND II trial for tricuspid regurgitation and groundbreaking insights...
Optimisation of your valve implantation to ensure lifelong outcomes using a novel self-expanding valve
24 Nov 2024 – From PCR London Valves 2024
Gain insights into the importance of valve optimization post-implantation to secure acute and long-term outcomes. In this session, you will discover the new features and benefits of the ACURATE Prime platform illustrated by a recorded case, and compare how different TAVI platforms perform when treating larger...
New data on TAVI
16 May 2024 – From EuroPCR 2024
This session presents the latest research and data on transcatheter aortic valve implantation (TAVI). It covers a range of topics, including long-term results of TAVI versus surgical aortic valve replacement in low-risk severe aortic stenosis, real-world experience with novel transcatheter heart valve devices, outcomes in patients...
Bicuspid disease - All you need to know
16 May 2024 – From EuroPCR 2024
This session is ideal if you want to understand the anatomical features of bicuspid aortic stenosis, learn about the latest post-TAVI clinical outcomes in bicuspid aortic valves, grasp key considerations for TAVI sizing in these cases, and analyze both self-expanding and balloon-expandable TAVI procedures in bicuspid...
Elevating quality of heart valve treatment through innovation: SAPIEN 3 Ultra RESILIA and EVOQUE valve systems
14 May 2024 – From EuroPCR 2024
Watch this session to explore how the SAPIEN 3 Ultra RESILIA valve can enhance lifetime management for patients, to find out more about the new treatment options available with the EVOQUE valve, identifying the patient populations that stand to benefit the most, and, additionally, to get...
What are the challenges for TAVI in bicuspid disease?
16 May 2024 – From EuroPCR 2024
Raj Makkar and Didier Tchétché address the complexities of bicuspid aortic valve disease, defining ideal candidates for TAVI or replacement and reviewing the NOTION-2 trial, which randomized younger, low-risk patients—including a significant number with bicuspid valves—to TAVI versus surgery. They highlight the importance of embolic protection...
Key questions in aortic valve intervention - How to navigate valve sequencing in younger patients?
21 Nov 2023 – From PCR London Valves 2023
What are the aspects to consider when treating younger patients? In this session, get both the interventional cardiologist's and the surgeon's perspective. What do we know and what do we need to know about valve sequencing and hemodynamics? What about CT planning and execution of redo-TAVI?...
Late-breaking trials on latest-generation aortic valves and dedicated transcatheter devices
20 Nov 2023 – From PCR London Valves 2023
Find out the outcomes of the main studies on the latest-generation valves and devices presented at PCR LV 2023 to better determine their benefits, performance and interest in the treatment of specific aortic pathologies: REACCESS-2 Study, ACURATE Neo2 PMCF post-market registry, OCEAN-TAVI registry, ShortCut Pivotal Study, and...
Mitral edge-to-edge repair using advanced imaging techniques
20 Nov 2023 – From PCR London Valves 2023
Second time TAVI (TAV-in-TAV) - Not as simple as it looks
19 Nov 2023 – From PCR London Valves 2023
Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...
Tricuspid Late-Breaking Trials: TRISCEND at 2 years, TEER in primary tricuspid regurgitation, TriCLASP, bRIGHT...
19 Nov 2023 – From PCR London Valves 2023
Discover the tricuspid late-breaking trials which were presented during PCR London Valves 2023:
- TRISCEND study two-year outcomes: transfemoral TTVR
- Transcatheter edge-to-edge repair in patients with primary tricuspid regurgitation
- One-year outcomes of transcatheter tricuspid valve repair from the TriCLASP study
- TTVR with the LuX-Valve system: one-year outcomes of a multicentre experience
- Real-world...
The catheter-based treatment revolution is just getting started
19 Nov 2023 – From PCR London Valves 2023
Consult this session to stay updated on the latest advancements in transcatheter aortic valve implantations and interventions for tricuspid regurgitation. Gain insights into how recent evidence and innovations are reshaping the treatment landscape for valvular heart disease.
Latest on TAVI in complex bicuspid lesions
17 May 2023 – From EuroPCR 2023
The bicuspid aortic valve is a real challenge in terms of diagnosis and treatment of patients, as discussed by Didier Tchétché and Raj Makkar in this interview.
Given that there are different phenotypes and patterns of calcification, some patients should indeed not be treated by TAVI: find out...
TAVI for bicuspid anatomy: beyond type I LR
17 May 2023 – From EuroPCR 2023
Consult this session if you want to understand the challenges of bicuspid aortic stenosis patients, type 0 in particular, to review contemporary sizing methods in bicuspid aortic stenosis, and to tailor the implant technique to individual patient.
TAVI in patients with long-life expectancy - LIVE case
16 May 2023 – From EuroPCR 2023
Watch the case of a 75-year-old male patient with history of TIA, symptomatic severe aortic stenosis with RBBB, and preserved LV function. The heart team's decision was to perform TAVI with PCI on LAD a few days before procedure.
First, a cerebral protection device (Sentinel) was implanted....
EuroPCR 2023 Hotlines / Late-Breaking Trials: TAVI
16 May 2023 – From EuroPCR 2023
Discover the conclusions of various studies and registries about TAVI: 5-year outcomes with the ACURATE neo2 valve: the Neo AS CE-mark study; TAVR in patients with cardiogenic shock which evaluated outcomes of consecutive TAVRs in patients with CS using contemporary SAPIEN 3 and SAPIEN 3 ultra...
Durability of surgical and transcatheter valves, what do we know so far?
16 May 2023 – From EuroPCR 2023
We have significant new data that highlights the long-lasting effectiveness of transcatheter devices, which brings forth a promising possibility of them competing with surgical valves in the next generation. Take part in a discussion with Bernard Prendergast and Raj Makkar as they analyze the data available so far...
Mitral innovations
29 Nov 2022 – From PCR London Valves 2022
Discover some innovative mitral interventions with this selection of cases: transcatheter mitral edge-to-edge repair under intracardiac echocardiography only, MitraClip procedure and other structural heart interventions in augmented reality, 3D simulation to guide TMVR in a patient with prior rheumatic heart disease and aortic dissection, and more!
TAVI challenges: session 4
29 Nov 2022 – From PCR London Valves 2022
This PCR LV 2022 session includes no less than 8 cases of TAVI complications, including TAVR in iatrogenic acute native pure aortic regurgitation, TAVI in a young patient after orthotopic liver retransplantation, or percutaneous treatment of a subaortic membrane using a self-expandable TAVR.
Transcatheter mitral valve interventions: clinical outcomes 2
28 Nov 2022 – From PCR London Valves 2022
This PCR LV 2022 session will enable you to discover outcomes of transcatheter edge-to-edge MVR in patients with right ventricle dysfunction, TEER for MR early after myocardial infarction, or a predictive selection of patients for TMVR, among others!
